mPEG-PLGA from PolySciTech used in development of nanoparticles for immunotherapy against cancer

 

Cancer has several mechanisms which allow it to evade the human immune system. Overcoming these attributes and triggering the immune system to attack the cancer cells directly is the goal of immunotherapy. Researchers at Chinese Academy of Sciences (Beijing) used PEG-PLGA (Cat# AK010) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create multi-functional nanoparticles which reduce cancers ability to evade the immune system. This research holds promise to improve therapy against cancer in the future. Read more: Li, L., Zhen, M., Wang, H., Sun, Z., Cao, X., Li, J., Liu, S., Zhao, Z., Zhou, C., Wang, C. and Bai, C., 2023. Tumor microenvironment-modulated multiple nanotherapeutic system for potent cancer immunotherapy and metastasis inhibition. Nano Today, 48, p.101702. https://www.sciencedirect.com/science/article/pii/S1748013222003309

“Abstract: The hypoxic and immunosuppressive tumor microenvironment (TME) generally weaken the efficacy of immunotherapy in solid tumors. However, reversing TME remains a formidable challenge. Here, an elaborately multitasking nanotherapeutic system (PEG-PLGA-R848@GFCNs) is demonstrated to forceful remodel TME. This nanotherapeutic system could validly relieve tumor hypoxia and induce M2 to M1 polarization of tumor-associated macrophages (TAMs) to reverse immunosuppression, serving for TME reprogramming. Furthermore, PEG-PLGA-R848@GFCNs stimulates dendritic cells maturation, thereby initiating T-cell-mediated anti-tumor immune response. Of note, the nanotherapeutic system eliminates primary tumor that established by 4T1 tumor models in mice and efficiently inhibits B16F10 melanoma metastasis without obvious adverse effects. Importantly, PEG-PLGA-R848@GFCNs combined with anti-PD-L1 immune checkpoint inhibitor achieves superior synergistic cancer immunotherapy. Collectively, our work offers a reliable and safe strategy to fabricate a multitasking nanotherapeutic system for comprehensively modulating TME to achieve effective cancer immunotherapy and metastasis inhibition.”

Video: https://youtu.be/tF-V4wB8ZwY